217 related articles for article (PubMed ID: 17549313)
1. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings.
Crescente M; Cerletti C; de Gaetano G
Thromb Haemost; 2007 Jun; 97(6):1054-6. PubMed ID: 17549313
[No Abstract] [Full Text] [Related]
2. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
3. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.
Kobzar G; Mardla V; Samel N
Platelets; 2011; 22(5):338-44. PubMed ID: 21557683
[TBL] [Abstract][Full Text] [Related]
4. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
[TBL] [Abstract][Full Text] [Related]
5. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery.
Zimmermann N; Wenk A; Kim U; Kienzle P; Weber AA; Gams E; Schrör K; Hohlfeld T
Circulation; 2003 Aug; 108(5):542-7. PubMed ID: 12874188
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
7. Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level. Functional and modelling studies.
Crescente M; Jessen G; Momi S; Höltje HD; Gresele P; Cerletti C; de Gaetano G
Thromb Haemost; 2009 Aug; 102(2):336-46. PubMed ID: 19652885
[TBL] [Abstract][Full Text] [Related]
8. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016).
Corazzi T; Leone M; Maucci R; Corazzi L; Gresele P
J Pharmacol Exp Ther; 2005 Dec; 315(3):1331-7. PubMed ID: 16144976
[TBL] [Abstract][Full Text] [Related]
9. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting.
Mattiello T; Guerriero R; Lotti LV; Trifirò E; Felli MP; Barbarulo A; Pucci B; Gazzaniga P; Gaudio C; Frati L; Pulcinelli FM
J Am Coll Cardiol; 2011 Aug; 58(7):752-61. PubMed ID: 21816313
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.
Pettinella C; Romano M; Stuppia L; Santilli F; Liani R; Davì G
Thromb Haemost; 2009 Apr; 101(4):687-90. PubMed ID: 19350112
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
[TBL] [Abstract][Full Text] [Related]
13. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients.
Ohmori T; Yatomi Y; Nonaka T; Kobayashi Y; Madoiwa S; Mimuro J; Ozaki Y; Sakata Y
J Thromb Haemost; 2006 Jun; 4(6):1271-8. PubMed ID: 16706971
[TBL] [Abstract][Full Text] [Related]
14. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
[TBL] [Abstract][Full Text] [Related]
15. Metabolomic investigation of the anti-platelet aggregation activity of ginsenoside Rk₁ reveals attenuated 12-HETE production.
Ju HK; Lee JG; Park MK; Park SJ; Lee CH; Park JH; Kwon SW
J Proteome Res; 2012 Oct; 11(10):4939-46. PubMed ID: 22873173
[TBL] [Abstract][Full Text] [Related]
16. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.
Guthikonda S; Lev EI; Patel R; DeLao T; Bergeron AL; Dong JF; Kleiman NS
J Thromb Haemost; 2007 Mar; 5(3):490-6. PubMed ID: 17319904
[TBL] [Abstract][Full Text] [Related]
17. Aspirin resistance.
Tantry US; Mahla E; Gurbel PA
Prog Cardiovasc Dis; 2009; 52(2):141-52. PubMed ID: 19732606
[No Abstract] [Full Text] [Related]
18. Differences in the influence of the interaction between acetylsalicylic acid and salicylic acid on platelet function in whole blood and isolated platelets: influence of neutrophils.
González-Correa JA; Muñoz-Marín J; López-Villodres JA; Navas MD; Guerrero A; Torres JA; De La Cruz JP
Pharmacol Res; 2007 Aug; 56(2):168-74. PubMed ID: 17644353
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin.
Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK
Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511
[TBL] [Abstract][Full Text] [Related]
20. Genetic variation in cyclooxygenase 1: effects on response to aspirin.
Halushka MK; Walker LP; Halushka PV
Clin Pharmacol Ther; 2003 Jan; 73(1):122-30. PubMed ID: 12545150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
